Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cebranopadol safety in cancer-related pain (CORAL XT)
NCT02031432Phase 3Completed
- Sponsor
- Tris Pharma
- Start
- Dec 2013
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, open-label, single-arm trial of cebranopadol in cancer pain, sponsored by Tris Pharma. Primary endpoint: Treatment Emergent Adverse Events at 28 weeks. Started Dec 2013; status: completed.
02
Drugs
cebranopadol
03
Conditions
cancer pain
Beyond the preview
Go deeper on NCT02031432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02031432.